ALLO-715

ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA).^[1] As of June 2021, it is undergoing clinical trials for the treatment of multiple myeloma.^[2] On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715.

Medical uses[]

CAR-T therapies target a patient's own T cells to respond to a particular antigen. Most CAR-T therapies on the market are autologous, that is, they rely on cells extracted from the patient, processed and reinfused. Tisagenlecleucel (Kymriah), for instance, is made by extracting the patient's blood, filtering T cells and processing them.^[3] Allogeneic CAR-T therapies may be able to dispense with this process through using TALEN gene editing technology and using T cells from healthy donors, obtained by leukapheresis. ALLO-715 is being investigated at Memorial Sloan Kettering Cancer Center as part of the UNIVERSAL trial for multiple myeloma, on its own and in conjunction with the selective gamma secretase inhibitor nirogacestat.^[2]

References[]

^ Sommer, Cesar; Boldajipour, Bijan; Valton, Julien; Galetto, Roman; Bentley, Trevor; Sutton, Janette; Ni, Yajin; Leonard, Mark; Van Blarcom, Thomas; Smith, Julianne; Chaparro-Riggers, Javier (2018-11-29). "ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma". Blood. 132 (Supplement 1): 591–591. doi:10.1182/blood-2018-99-119227. ISSN 0006-4971.
^ Jump up to: ^a ^b Allogene Therapeutics (2021-06-23). "A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma". Cite journal requires |journal= (help)
^ Ledford, Heidi (2017-07-01). "Engineered cell therapy for cancer gets thumbs up from FDA advisers". Nature. 547 (7663): 270–270. doi:10.1038/nature.2017.22304. ISSN 1476-4687.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] Sommer, Cesar; Boldajipour, Bijan; Valton, Julien; Galetto, Roman; Bentley, Trevor; Sutton, Janette; Ni, Yajin; Leonard, Mark; Van Blarcom, Thomas; Smith, Julianne; Chaparro-Riggers, Javier (2018-11-29). "ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma". Blood. 132 (Supplement 1): 591–591. doi:10.1182/blood-2018-99-119227. ISSN 0006-4971.

[universal-trial-2] Jump up to: ^a ^b Allogene Therapeutics (2021-06-23). "A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma". Cite journal requires |journal= (help)

[3] Ledford, Heidi (2017-07-01). "Engineered cell therapy for cancer gets thumbs up from FDA advisers". Nature. 547 (7663): 270–270. doi:10.1038/nature.2017.22304. ISSN 1476-4687.

[1]

[2]

[3]